Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are
increasingly being used as preventive treatments for migraine. Their effectiveness and …

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …

Background Criteria, including clinical features and effective outcomes, for access and
persistence of novel but costly treatments may vary between countries, thus affecting the …

Abstract Background and Purpose To evaluate the 1‐year effectiveness and tolerability of
galcanezumab in real life and the prognostic indicators of persistent response. Methods …

Background Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a
favourable option for patients with migraine who experience distressful headache disability …

Background Erenumab has demonstrated effectiveness for prevention of migraine attacks,
but the treatment is costly, and a considerable proportion of patients do not respond to it. The …

Background Real-world data are accumulating on the effectiveness, tolerability and safety of
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …

Objective To investigate in real-life the conversion from chronic migraine (CM) to episodic
migraine (EM), specifically to EM with High-Frequency (HFEM: 8–14 monthly migraine days …

Background Medication overuse headache significantly contributes to the chronification
process and treatment refractoriness of migraine. Currently, abrupt discontinuation of the …

Background: Calcitonin gene-related peptide (CGRP) targeted therapies are an important
breakthrough in migraine prevention. Randomized clinical trials, post-hoc analyses, and …